Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.

作者: K-H Yeh , S-H Yeh , C-H Hsu , T-M Wang , I-F Ma

DOI: 10.1054/BJOC.2000.1456

关键词:

摘要: We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m-2 week-1 and leucovorin 500 week-1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify possible mechanism underlying improved activity compared with conventional regimens, we conducted vitro studies examining effect these regimens on differential regulation thymidylate synthase (TS) NCI-N87, a human cancer cell line. The expected serum concentrations are 100-200 mM (lasting for less than 30 min) 5-10 24 h) (bolus injection or short intravenous infusion 370-500 m-2) respectively. Western blot analysis revealed exposure NCI-N87 to 2.5-10.0 resulted dose-dependent depletion free TS, lasting more h. In contrast, 30-min 200 12-h TS. Moreover, higher S-phase blockade enhanced cytotoxicity. both modes treatment, initial rapid TS was accompanied by increment higher-molecular-weight molecule, suggesting formation ternary complex key action during this period. Northern showed steady-state mRNA not affected either schedules. conclude cells low concentration better suppression degree blockade, cytotoxicity high 5-FU. These results may help explain clinical efficacy regimens.

参考文章(34)
L.G. Navalgund, C. Rossana, A.J. Muench, L.F. Johnson, Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. Journal of Biological Chemistry. ,vol. 255, pp. 7386- 7390 ,(1980) , 10.1016/S0021-9258(20)79715-2
Patrick G Johnston, Chi-Ming Liang, Sally Henry, Bruce A Chabner, Carmen J Allegra, None, Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Research. ,vol. 51, pp. 6668- 6676 ,(1991)
H J Lenz, C G Leichman, K D Danenberg, P V Danenberg, S Groshen, H Cohen, L Laine, P Crookes, H Silberman, J Baranda, Y Garcia, J Li, L Leichman, Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. Journal of Clinical Oncology. ,vol. 14, pp. 176- 182 ,(1996) , 10.1200/JCO.1996.14.1.176
P G Johnston, E R Fisher, H E Rockette, B Fisher, N Wolmark, J C Drake, B A Chabner, C J Allegra, The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Journal of Clinical Oncology. ,vol. 12, pp. 2640- 2647 ,(1994) , 10.1200/JCO.1994.12.12.2640
C H Köhne, P Schöffski, H Wilke, C Käufer, R Andreesen, U Ohl, U Klaasen, M Westerhausen, W Hiddemann, G Schott, A Harstick, J Bade, A Horster, U Schubert, H Hecker, B Dörken, H J Schmoll, Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. Journal of Clinical Oncology. ,vol. 16, pp. 418- 426 ,(1998) , 10.1200/JCO.1998.16.2.418
A de Gramont, J F Bosset, C Milan, P Rougier, O Bouché, P L Etienne, F Morvan, C Louvet, T Guillot, E François, L Bedenne, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology. ,vol. 15, pp. 808- 815 ,(1997) , 10.1200/JCO.1997.15.2.808
Edward Chu, Carmen J. Allegra, The role of thymidylate synthase in cellular regulation Advances in Enzyme Regulation. ,vol. 36, pp. 143- 163 ,(1996) , 10.1016/0065-2571(95)00004-6
A de Gramont, C Louvet, T André, C Tournigand, M Krulik, A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a Regimen European Journal of Cancer. ,vol. 34, pp. 619- 626 ,(1998) , 10.1016/S0959-8049(97)00364-X
W. Li, J. Fan, D. Hochhauser, D. Banerjee, Z. Zielinski, A. Almasan, Y. Yin, R. Kelly, G. M. Wahl, J. R. Bertino, Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 10436- 10440 ,(1995) , 10.1073/PNAS.92.22.10436